Lecointre L, Veltenb M, Lodi M, et al. - Researchers conducted this retrospective, multicenter cohort study to contrast two groups of patients presenting advanced ovarian carcinoma benefiting from neoadjuvant chemotherapy (NAC) followed by cytoreductive surgery: after 3–4 cycles (group 1) or ≥ 5 cycles (group 2), regarding overall survival and progression-free survival (PFS), surgical complications and the extent of cytoreduction were evaluated. This investigation was performed in nine referral centers of France, reviewing the charts of all patients who had NAC between January 2000 and June 2017. Of 501 individuals involved, 236 benefited from ≤ 4 NAC cycles and 265 from ≥ 5 NAC cycles. Patients receiving late IDS (≥ 5 NAC cycles) appear to exhibit a poorer prognosis compared with those operated on earlier in a large series of advanced ovarian cancer. By optimal resection and response to chemotherapy, the survival seems to be mainly determined. Data reported that 5-year PFS was 19.7% and 11.7% respectively.